A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

Psychopharmacology

Volumn 220, Issue 3, 2012, Pages 591-598

  Arbabi, Mohammad ^a   Bagheri, Mohaddeseh ^a   Rezaei, Farzin ^b   Ahmadi Abhari, Seyyed Ali ^a   Tabrizi, Mina ^c   Khalighi Sigaroudi, Farahnaz ^d   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Chronic schizophrenia; Modafinil; Negative symptoms

Indexed keywords

MODAFINIL; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, PSYCHIATRIC; HOSPITALS, TEACHING; HUMANS; IRAN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858405528     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2513-z     Document Type: Article

References (27)

1. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S (2011) Doubleblind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety 28:297-302
2. Akhondzadeh S (2006) Pharmacotherapy of schizophrenia: the past, present and future. Curr Drug Therapy 1:1-7
3. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH (2006) Correlation between testosterone, gonadotro-pins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 84:405-410
4. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi-Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185 (Pubitemid 46177578)
5. Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA (2011) Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychophar-macology 213:809-815
6. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn., text revision. American Psychiatric Association, Washington, DC
7. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for attention-deficit/ hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuro-psychopharmacol Biol Psychiatry 32:145-149
8. Ballon JS, Feifel D (2006) A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67:554-666
9. Buckley PF, Stahl SM (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 115:93-100 (Pubitemid 46114869)
10. Chouinard G, Ross-Chouinard A, Annables L, Jones BD (1980) Extrapyramidal symptoms rating scale (abstract). Can J Neurol Sci 7:233
11. de Saint ZH, Martine O, Claude R, Gérard B, Stylianos N (2001) Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 12:3533-3537
12. Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC (2009) Modafinil for clozapine-treated schizophrenia patie6nts: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 70:1674-1680
13. Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S (2010) A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol 30:678-682
14. Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168:234-237
15. Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS (2010) Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, doubleblind, placebo-controlled study. J Clin Psychiatry 71:1475-1481
16. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull 13:261-276 (Pubitemid 18039085)
17. Kumar R (2008) Approved and investigational uses of modafinil: an evidence-based review. Drugs 68:1803-1839
18. Mariani JJ, Hart CL (2005) Psychosis associated with modafinil and shift work. Am J Psychiatry 162:1983 (Pubitemid 41428636)
19. Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochem-ical actions and effects on cognition. Neuropsychopharmacology 33:1477-1502 (Pubitemid 351684703)
20. Mohammadi MR, Akhondzadeh S (2001) Schizophrenia: etiology and pharmacotherapy I. Drugs 4:1167-1172
21. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR (2007) A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 68:705-710 (Pubitemid 46841853)
22. Rosenthal MH, Bryant SL (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 27:38-43 (Pubitemid 38280387)
23. Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP (2009) Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 70:104-112
24. Spence SA, Green RD, Wilkinson ID, Hunter MD (2005) Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187:55-61 (Pubitemid 41002514)
25. Tattan TM, Creed FH (2001) Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 27:149-155 (Pubitemid 32199270)
26. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsycho-pharmacology 29:1363-1373 (Pubitemid 38780659)
27. Wu P, Jones S, Ryan CJ, Michail D, Robinson TD (2008) Modafinil-induced psychosis. Intern Med J 38:677-678